Riverwater Partners LLC Sells 172 Shares of Hologic, Inc. (NASDAQ:HOLX)

Riverwater Partners LLC decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,410 shares of the medical equipment provider’s stock after selling 172 shares during the period. Riverwater Partners LLC’s holdings in Hologic were worth $390,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in HOLX. General Partner Inc. acquired a new position in shares of Hologic during the fourth quarter worth approximately $26,000. Venturi Wealth Management LLC lifted its holdings in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the period. Finally, Smithfield Trust Co raised its position in shares of Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on HOLX. Stephens reiterated an “overweight” rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Raymond James reiterated an “outperform” rating and set a $90.00 price target (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a report on Thursday, February 6th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Down 1.3 %

Shares of NASDAQ:HOLX opened at $60.86 on Friday. The firm has a market cap of $13.66 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $59.06 and a 12 month high of $84.67. The company’s fifty day simple moving average is $64.30 and its 200 day simple moving average is $72.65.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.